Literature DB >> 15237589

Low expression of p63 and p73 in osteosarcoma.

Hye-Rim Park1, Youn-Wha Kim, Jae-Hoon Park, Young-Hee Maeng, Takayuki Nojima, Hiroshi Hashimoto, Yong-Koo Park.   

Abstract

BACKGROUND: The recent discovery of two p53-related genes, p63 and p73, has revealed an additional level of complexity to the study of p53 function. Both genes encode multiple proteins arising from alternative promoter usage and splicing, with transactivation, DNA-binding, and tetramerization domains. Recent data support a role for p63 in squamous and transitional cell carcinomas, as well as in certain lymphomas and thymomas.
METHODS: To characterize the involvement of p63 and p73 in the development of osteosarcoma, we analyzed the expression and mutation of TAp63 and TAp73 in six osteosarcoma cell lines and twelve osteosarcoma specimens.
RESULTS: Semiquantitative DNA/PCR analysis revealed that eight (67%) and six (50%) out of twelve osteosarcoma specimens showed significantly reduced levels of p63 and p73 transcription, respectively. Direct sequencing of the entire coding region detected no mutations in cell lines or osteosarcoma specimens.
CONCLUSIONS: Our data suggest that low expression of p63 and p73 is relatively common in osteosarcomas and might contribute to their molecular pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15237589     DOI: 10.1177/030089160409000214

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  9 in total

1.  Nuclear p63 expression in osteoblastic tumors.

Authors:  Michael E Kallen; Melinda E Sanders; Adriana L Gonzalez; Jennifer O Black; Vicki L Keedy; Kenneth R Hande; Kelly C Homlar; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Cheryl M Coffin; Justin M M Cates
Journal:  Tumour Biol       Date:  2012-05-25

Review 2.  Clinical implications of the deregulated TP73 isoforms expression in cancer.

Authors:  N Rodríguez; A Peláez; R Barderas; G Domínguez
Journal:  Clin Transl Oncol       Date:  2017-12-11       Impact factor: 3.405

3.  TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs.

Authors:  Xiaohua Su; Deepavali Chakravarti; Min Soon Cho; Lingzhi Liu; Young Jin Gi; Yu-Li Lin; Marco L Leung; Adel El-Naggar; Chad J Creighton; Milind B Suraokar; Ignacio Wistuba; Elsa R Flores
Journal:  Nature       Date:  2010-10-21       Impact factor: 49.962

4.  Regulation of VDR by deltaNp63alpha is associated with inhibition of cell invasion.

Authors:  Ramakrishna Kommagani; Mary K Leonard; Stefanie Lewis; Rose-Anne Romano; Satrajit Sinha; Madhavi P Kadakia
Journal:  J Cell Sci       Date:  2009-07-21       Impact factor: 5.285

5.  A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained.

Authors:  André Maues De Paula; Alexandre Vasiljevic; Roch Giorgi; Anne Gomez-Brouchet; Sébastien Aubert; Xavier Leroy; Hélène Duval; Gonzague de Pinieux; Corinne Bouvier
Journal:  Virchows Arch       Date:  2014-08-07       Impact factor: 4.064

Review 6.  p73 as a pharmaceutical target for cancer therapy.

Authors:  Andrea Bisso; Licio Collavin; Giannino Del Sal
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function.

Authors:  Hong Wu; Roger P Leng
Journal:  Oncotarget       Date:  2015-08-28

Review 8.  The Regulation of Tumor Suppressor p63 by the Ubiquitin-Proteasome System.

Authors:  Stephen R Armstrong; Hong Wu; Benfan Wang; Yasser Abuetabh; Consolato Sergi; Roger P Leng
Journal:  Int J Mol Sci       Date:  2016-12-06       Impact factor: 5.923

9.  p73 - NAV3 axis plays a critical role in suppression of colon cancer metastasis.

Authors:  Apoorva Uboveja; Yatendra Kumar Satija; Fouzia Siraj; Ira Sharma; Daman Saluja
Journal:  Oncogenesis       Date:  2020-02-06       Impact factor: 7.485

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.